Magazine Article | December 1, 2023

Executive Outlook: Converting Innovative Science Into Predictable Returns

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

It’s not all doom and gloom as 2023 comes to a close, although there is plenty of both to go around. Generalist investors haven’t found their way back to the sector, and a record number of biotechs declared bankruptcy this year. CMS selected the first round of drugs for price negotiation under the Inflation Reduction Act (IRA), and payer concerns about drug budgets in the context of innovative, late-stage therapies in industry pipelines are generating downward pricing pressure on multiple fronts, both private and public.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader